Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Cisplatin and Radiation for HIV-Associated Cervical Cancer
NCT01590017Phase 2Completed
- Sponsor
- AIDS Malignancy Consortium
- Start
- Apr 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cisplatin in Cervical Cancer (CC), sponsored by AIDS Malignancy Consortium. Primary endpoints: Treatment Completion Rate at 8 weeks and Patients With Adverse Events at 12 months. Started Apr 2014; status: completed.
02
Drugs
cisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT01590017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01590017.